Core Viewpoint - Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Sight Sciences, Inc. due to significant stock decline following the company's recent financial disclosures [1][4]. Financial Performance - On March 4, 2026, Sight Sciences reported its fourth quarter and full year 2025 financial results, projecting total revenue for fiscal year 2026 to be approximately $82 million to $88 million, which includes $5 million to $7 million in Interventional Dry Eye revenue related to the TearCare platform [3]. Stock Performance - Following the financial disclosures, Sight Sciences' common stock experienced a significant decline, prompting the investigation into whether the company complied with federal securities laws [4].

Core Insights - The company achieved a significant reimbursement milestone in Q4 with the establishment of pricing for CPT code 0563T related to the TearCare procedure, marking a turning point in its strategy to lead the reimbursed interventional dry eye treatment market [1] - The business segments have been redefined from "surgical glaucoma" and "dry eye" to "interventional glaucoma" and "interventional dry eye," reflecting a focus on earlier procedure-based interventions [2] Financial Performance - In Q4 2025, total revenue was $20.4 million, representing a 7% year-over-year increase, with adjusted operating expenses down 23% to $18.9 million and a net loss narrowed to $4.2 million [3][13] - Interventional glaucoma revenue was $19.7 million, up 5% year-over-year, while interventional dry eye revenue was $0.7 million, showing growth from $0.3 million in the prior year [4][5] - The company has provided 2026 revenue guidance of $82 million to $88 million, indicating a growth of 6% to 14% compared to 2025 [11] Strategic Focus - Management is emphasizing operational discipline and cash management, with a cash position of $92 million at the end of Q4 [3][13] - The company is targeting high-volume dry eye prescribers and engaging new providers in states with established fee schedules, leveraging existing glaucoma customers for TearCare adoption [6] - An "interventional glaucoma evaluation workflow" is being developed to enhance standalone adoption in the glaucoma market [9][10] Market Dynamics - The interventional glaucoma segment is expected to grow low single digits in Q1 2026, with a stronger performance anticipated in the second half of the year [11] - The company is focusing on expanding the standalone glaucoma market and investing in targeted commercial resources [9]

Core Insights - Sight Sciences, Inc. reported revenue of $20.39 million for the quarter ended December 2025, reflecting a year-over-year increase of 6.9% and a surprise of +0.34% over the Zacks Consensus Estimate of $20.32 million [1] - The company's EPS was -$0.08, an improvement from -$0.23 in the same quarter last year, with a surprise of +44.83% compared to the consensus estimate of -$0.15 [1] Revenue Performance - Revenue from Interventional Dry Eye was $0.72 million, exceeding the average estimate of $0.6 million by four analysts, representing a significant year-over-year increase of +138.2% [4] - Revenue from Interventional Glaucoma was reported at $19.66 million, slightly below the average estimate of $19.7 million, with a year-over-year increase of +4.8% [4] Profit Metrics - Gross Profit from Interventional Dry Eye was $0.5 million, surpassing the estimated $0.3 million by three analysts [4] - Gross Profit from Interventional Glaucoma was $17.29 million, exceeding the average estimate of $16.89 million by three analysts [4] Stock Performance - Over the past month, shares of Sight Sciences have returned -18.7%, compared to a -1.3% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [3]

分组1 - Sight Sciences, Inc. reported a quarterly loss of $0.08 per share, better than the Zacks Consensus Estimate of a loss of $0.15, and improved from a loss of $0.23 per share a year ago, resulting in an earnings surprise of +44.83% [1] - The company achieved revenues of $20.39 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 0.34% and showing an increase from $19.07 million in the same quarter last year [2] - Sight Sciences has consistently exceeded consensus EPS estimates over the last four quarters, indicating strong performance in earnings expectations [2] 分组2 - The stock has underperformed, losing about 33.7% since the beginning of the year, compared to a decline of 0.4% in the S&P 500 [3] - The company's earnings outlook is crucial for investors, with current consensus EPS estimates at -$0.18 for the coming quarter and -$0.59 for the current fiscal year [7] - The Medical - Instruments industry, to which Sight Sciences belongs, is currently ranked in the top 32% of over 250 Zacks industries, suggesting a favorable industry outlook [8]

Core Insights - The company ended 2025 with strong execution, achieving revenue growth in both interventional glaucoma and interventional dry eye segments, and aims for double-digit growth in 2026 while maintaining operational discipline [1][16] - The interventional technologies, OMNI and TearCare, target prevalent diseases such as glaucoma and dry eye, presenting significant long-term market opportunities [1][5] Financial Performance - Total revenue for Q4 2025 was $20.4 million, a 7% increase year-over-year, with interventional glaucoma revenue at $19.7 million (up 5%) and interventional dry eye revenue at $700,000 (up from $300,000) [17][18] - Gross margins were strong, with interventional glaucoma at 88% and interventional dry eye improving to 68% [18] - Operating expenses decreased by 25% to $21.5 million, reflecting cost management efforts, including a reduction in force [18][19] Market Strategy - The company is focusing on interventional glaucoma and interventional dry eye, with a strategy to enhance customer engagement and expand market access [6][12] - The interventional dry eye segment is expected to grow significantly, with a revenue guidance of $5 million to $7 million for 2026, compared to $1.6 million in the prior year [20] - The company aims to pioneer the reimbursed interventional dry eye market, having established pricing for the TearCare procedure with two MACs [8][12] Growth Drivers - The interventional glaucoma market is expected to grow in the low- to mid-single digits, with a focus on expanding the combo cataract segment and standalone market opportunities [20][26] - The company is investing in commercial infrastructure to support growth in both interventional segments, particularly in areas with established reimbursement [12][41] - The potential for TearCare is significant, with an estimated 700,000 patients in the targeted MAC regions suffering from moderate to severe dry eye disease [44][50] Future Outlook - Revenue guidance for 2026 is set at $82 million to $88 million, reflecting a growth of 6% to 14% compared to 2025 [20][22] - The company anticipates that the first quarter of 2026 will be the lowest for interventional glaucoma, with expectations for growth in the second half of the year [21][56] - Continued engagement with additional MACs and commercial payers is critical for expanding access and accelerating adoption of interventional dry eye treatments [12][61]

Financial Data and Key Metrics Changes - In Q4 2025, total revenue was $20.4 million, a 7% increase year-over-year [17] - Interventional glaucoma revenue was $19.7 million, up 5% year-over-year, while interventional dry eye revenue was $0.7 million, up from $0.3 million [17][19] - Gross margin was 87%, consistent with the prior year, with interventional glaucoma gross margin at 88% and interventional dry eye gross margin improved to 68% from 51% [18] - Total operating expenses decreased by 25% to $21.5 million compared to $28.5 million in the prior year [18] - Net loss was $4.2 million or $0.08 per share, compared to a net loss of $11.8 million or $0.23 per share in the previous year [19] Business Line Data and Key Metrics Changes - Interventional dry eye revenue in Q4 was driven by the sale of approximately 700 Smart Lids to about 80 accounts, with 30 being new engagements [9][10] - Interventional glaucoma revenue growth was supported by a 2% increase in ordering accounts and higher average selling prices [14] - The company is focused on expanding the interventional dry eye market through investments in commercial infrastructure and provider engagement [11][12] Market Data and Key Metrics Changes - The interventional glaucoma market is expected to grow in the low to mid-single digits, while the interventional dry eye segment is projected to reach $5 million-$7 million in revenue for 2026 [20][26] - The company estimates that the current MIGS market is approximately 90% combo cataract and 10% standalone, with expectations for a shift towards standalone procedures [37] Company Strategy and Development Direction - The company aims to return to double-digit growth while maintaining operational rigor and financial discipline [5] - A focus on interventional solutions is expected to create multiple durable growth drivers across glaucoma and dry eye categories [7] - The company is investing in targeted commercial resources to drive education and activation in the standalone glaucoma market [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving cash flow breakeven without raising additional equity capital, supported by a strong balance sheet [17] - The company is optimistic about the growth potential in both interventional glaucoma and interventional dry eye markets, with a focus on disciplined execution [22] - Management highlighted the importance of expanding market access and engaging with additional MACs and commercial payers throughout 2026 [12][22] Other Important Information - The company has established pricing for CPT code 0563T associated with the TearCare procedure, marking a significant milestone for the interventional dry eye business model [9] - The company ended Q4 with $92 million in cash and cash equivalents, down from $120.4 million at the end of 2024 [19] Q&A Session Summary Question: Guidance assumptions for interventional glaucoma and interventional dry eye - Management indicated a stable market for interventional glaucoma and expressed excitement about growth in both segments for 2026 [25][26] Question: Underlying market growth assumptions for interventional glaucoma - Management estimates low to mid-single digit market growth for interventional glaucoma [27] Question: Standalone glaucoma market evolution and obstacles - Management discussed the need for education and activation to convert understanding of interventions into actual cases, with a focus on procedural workflows [34][36] Question: Operating expenses and investment balance - Management emphasized a focus on commercial infrastructure investments while maintaining financial discipline [44][46] Question: Revenue opportunity in MACs for dry eye - Management highlighted a significant market opportunity in MACs with 10.4 million covered lives and a high prevalence of dry eye disease [47][49] Question: Peak sales potential for TearCare - Management acknowledged the large market opportunity for TearCare but refrained from quantifying peak sales potential at this time [55][56] Question: Impact of new goniotomy codes on reimbursement - Management discussed potential changes in reimbursement for goniotomy and its implications for OMNI technology [69][70]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $20.4 million, a 7% increase year-over-year [17] - Interventional glaucoma revenue was $19.7 million, up 5% year-over-year, driven by increases in ordering accounts and average selling prices [17] - Interventional dry eye revenue was $0.7 million, up from $0.3 million, reflecting positive traction in the reimbursed interventional dry eye business model [17] - Gross margin was 87%, consistent with the prior year, while interventional glaucoma gross margin improved to 88% from 87% [18] - Total operating expenses decreased by 25% to $21.5 million compared to $28.5 million in the prior year [18] - Net loss was $4.2 million or $0.08 per share, compared to a net loss of $11.8 million or $0.23 per share in the previous year [19] Business Line Data and Key Metrics Changes - Interventional dry eye segment achieved a significant reimbursement milestone with established pricing for CPT code 0563T, associated with the TearCare procedure [9] - Revenue from interventional dry eye in Q4 was driven by the sale of approximately 700 SmartLids to about 80 accounts, with around 30 being new engagements [9][10] - Interventional glaucoma revenue growth was supported by a 2% increase in ordering accounts year-over-year, with utilization remaining healthy [14] Market Data and Key Metrics Changes - The interventional glaucoma market is expected to grow in the low to mid-single digits, while the interventional dry eye market is anticipated to grow significantly due to new reimbursement opportunities [25][26] - The current MIGS market is estimated to be 90% combo cataract and 10% standalone, with expectations for a shift towards standalone procedures [36] Company Strategy and Development Direction - The company aims to return to double-digit growth while maintaining operational rigor and financial discipline [5] - A focus on interventional solutions is expected to create multiple durable growth drivers across glaucoma and dry eye treatments [7] - Investments in commercial infrastructure and market access are planned to support growth in both interventional dry eye and interventional glaucoma segments [22][44] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving cash flow breakeven without raising additional equity capital, emphasizing operational discipline [17] - The company is optimistic about the growth potential in both segments, particularly with the recent reimbursement milestones for interventional dry eye [22] - Management highlighted the importance of educating eye care providers on the benefits of earlier intervention with minimally invasive solutions for glaucoma [33] Other Important Information - The company ended Q4 2025 with $92 million in cash and cash equivalents, down from $120.4 million at the end of 2024 [19] - The company initiated revenue guidance for 2026 of $82 million to $88 million, reflecting growth of 6% to 14% compared to 2025 [20] Q&A Session Summary Question: Guidance assumptions for interventional glaucoma and interventional dry eye - Management indicated a stable market for interventional glaucoma and emphasized prudent guidance for interventional dry eye, which is still early in its reimbursement journey [25][26] Question: Standalone glaucoma market evolution and obstacles - Management noted that activating the standalone market requires education and a structured workflow similar to cataract surgery, with ongoing investments to facilitate this transition [33][36] Question: Operating expenses and investment balance - Management confirmed that investments in commercial infrastructure will focus on both interventional dry eye and glaucoma, while maintaining financial discipline [42][44] Question: TearCare peak sales potential - Management acknowledged the large market opportunity for TearCare but refrained from quantifying peak sales potential at this time, emphasizing the need for market access [52][54] Question: First quarter outlook for interventional glaucoma - Management cited weather-related disruptions as a factor impacting the first quarter outlook, but did not foresee other significant headwinds [59]

Financial Data and Key Metrics Changes - In Q4 2025, total revenue was $20.4 million, a 7% increase year-over-year [17] - Interventional glaucoma revenue was $19.7 million, up 5% year-over-year, while interventional dry eye revenue was $0.7 million, up from $0.3 million [17] - Gross margin was 87%, consistent with the prior year, with interventional glaucoma gross margin at 88% and interventional dry eye gross margin improved to 68% from 51% [18] - Total operating expenses decreased by 25% to $21.5 million compared to $28.5 million in the prior year [18] - Net loss was $4.2 million or $0.08 per share, compared to a net loss of $11.8 million or $0.23 per share in the previous year [19] - Cash and cash equivalents at the end of the quarter were $92 million, down from $120.4 million at the end of 2024 [19] Business Line Data and Key Metrics Changes - Interventional dry eye revenue in Q4 was $0.7 million, driven by the sale of approximately 700 Smart Lids to about 80 accounts, with 30 being new engagements [9][10] - Interventional glaucoma revenue was $19.7 million, with ordering accounts increasing by 2% year-over-year [13] - Utilization in interventional glaucoma remained healthy, down slightly after a strong Q3 [13] Market Data and Key Metrics Changes - The interventional dry eye market is expected to grow significantly, with a focus on expanding market access and engaging new eye care providers [11][12] - The interventional glaucoma market is projected to grow in the low to mid-single digits, with a focus on expanding the combo cataract segment and standalone market opportunities [25][27] Company Strategy and Development Direction - The company aims to return to double-digit growth while maintaining operational rigor and financial discipline [5] - A shift in terminology from surgical glaucoma and dry eye to interventional glaucoma and interventional dry eye reflects a focus on earlier procedure-based interventions [6] - Investments are being made in commercial infrastructure to support growth in both interventional dry eye and interventional glaucoma segments [21][45] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term opportunity within the interventional markets for glaucoma and dry eye, emphasizing the importance of their proprietary technologies [5][6] - The company is focused on pioneering the reimbursed interventional dry eye treatment market and enhancing customer engagement [11][12] - Management expects revenue guidance for 2026 to be between $82 million and $88 million, reflecting growth of 6% to 14% compared to 2025 [19][20] Other Important Information - The company has established pricing for CPT code 0563T associated with the TearCare procedure, marking a significant milestone for the interventional dry eye business model [9] - The company is actively engaging with additional MACs and commercial payers to accelerate adoption and expand access for patients [12][63] Q&A Session Summary Question: Can you provide color on low-end versus high-end assumptions for guidance? - Management indicated a stable market for interventional glaucoma and emphasized prudent guidance for interventional dry eye, which is still early in its market access journey [25][26] Question: What are the assumptions for underlying market growth in interventional glaucoma? - Management estimates low to mid-single digit market growth for interventional glaucoma [27] Question: How do you see the standalone glaucoma market evolving? - Management highlighted the importance of educating eye care providers on earlier interventions and activating the standalone market through targeted investments [34][36] Question: What is the revenue opportunity for dry eye in the two MACs? - Management noted a significant opportunity with 10.4 million covered lives and approximately 700,000 patients with moderate to severe MGD in those markets [46] Question: Can you discuss the peak sales potential of TearCare? - Management acknowledged the large market opportunity for TearCare but refrained from quantifying peak sales potential at this time [51][54] Question: What is the expectation for reimbursement with new goniotomy codes? - Management is aware of the potential impact of new goniotomy codes and expects some pressure on utilization but believes it could also create a tailwind for their OMNI technology [66]

Financial Performance - For the years ended December 31, 2025 and 2024, the company reported net losses of $38.4 million and $51.5 million, respectively, with an accumulated deficit of $384.7 million as of December 31, 2025[151]. - The company expects to continue incurring losses for the foreseeable future and cannot assure achieving or sustaining profitability, which could adversely affect its financial condition and results of operations[152]. - As of December 31, 2025, the company had $92.0 million in cash and cash equivalents and an accumulated deficit of $384.7 million, indicating ongoing financial challenges[230]. - The company has an aggregate principal borrowing of approximately $40.0 million outstanding under the Hercules Loan Agreement, with an interest expense of $5.1 million and $4.7 million for the years ended December 31, 2025 and 2024, respectively[247]. - The company’s ability to generate cash flow from operations is critical for servicing its debt obligations, which may be impacted by various external factors[250]. Revenue and Market Dynamics - Revenue is highly dependent on the sales of OMNI and TearCare products, with expectations that these will account for substantially all revenue in the next 12 months[153]. - Recent changes in Medicare coverage determinations have resulted in a reduction in overall MIGS claims volumes, adversely impacting the company's revenue and prospects[155]. - The company faces adverse effects on the MIGS device market due to non-coverage policies from two MACs, potentially leading to a further decline in claims volumes[167]. - Revenue from TearCare is dependent on adequate coverage and reimbursement, with two MACs currently establishing fee schedules that reflect the procedure's cost and value[169]. - The total addressable market for the company's products may be smaller than estimated, which could adversely affect sales growth and financial performance[209]. Regulatory and Compliance Challenges - Regulatory compliance is critical, as failure to meet FDA requirements could result in enforcement actions, including fines, recalls, or suspension of production[294]. - The company is subject to various federal, state, and foreign laws regarding healthcare fraud and abuse, which could lead to substantial penalties and adverse publicity[315]. - Non-compliance with regulatory requirements could lead to enforcement actions, including fines, recalls, and potential inability to market products, significantly impacting sales and reputation[305]. - The complexity and stringency of regulatory requirements have increased over time, potentially leading to higher costs and lower sales if compliance is not maintained[305]. - The company must inform the notified body of any substantial changes to its quality system or medical devices that could affect compliance with EU regulations[299]. Competition and Market Position - The company competes with established firms that may have greater resources and established products, which could hinder market penetration and operating results[180]. - Established treatment patterns for glaucoma and MGD may limit the adoption of the company's products, requiring significant education efforts for ECPs[183]. - The market for the company's products is highly competitive, with potential competitors developing new technologies that could gain greater acceptance[176]. - The company is aware of competitors potentially seeking to use CPT code 0563T for their products, which could adversely affect its market position[181]. - The company faces significant competition and must effectively manage pricing pressures and reimbursement changes to sustain growth[220]. Operational and Supply Chain Risks - The reliance on third-party suppliers, particularly in China, poses risks related to tariffs and supply chain disruptions that could adversely impact gross margins[192]. - A significant new tariff on products imported from China was imposed in February 2025, increasing costs and potentially affecting gross margins[196]. - The identification and qualification of new manufacturing facilities may be time-consuming and could disrupt operations, affecting product supply and quality[199]. - The company does not typically enter into long-term supply agreements with manufacturers, increasing the risk of supply disruptions[201]. - If demand for products increases, the company may struggle to manage manufacturing processes efficiently, potentially leading to fluctuations in sales and operating margins[202]. Strategic Initiatives and Future Plans - The company is focused on expanding commercialization efforts and developing new products, but faces challenges due to limited experience and market penetration[156]. - The company plans to invest in clinical trials and research and development for product improvements and future products, which will increase expenses[231]. - The company plans to expand its international sales through a combination of direct sales personnel and independent distributors, aiming to grow its customer base and increase adoption by existing customers[204]. - Significant resources will be dedicated to sales and marketing initiatives, with a focus on educational programs through leading medical publications and industry meetings[205]. - The company is pursuing a long-term market development plan for TearCare, focusing on partnerships for prior authorization approvals, but success is not guaranteed[170]. Human Resources and Management - The company relies on its senior management team, and the loss of key employees could negatively affect its business and operations[241]. - The company may experience difficulties in attracting and retaining skilled employees due to competition, which could hinder its growth and operational effectiveness[242]. - The company anticipates hiring additional accounting and financial staff with public company experience to support future growth[331]. Legal and Intellectual Property Issues - The company relies on patent protection for its technology, but uncertainties in patent law and potential litigation could impair its competitive advantage[273][276]. - Ongoing intellectual property litigation could incur significant costs and distract management from core business activities, impacting overall performance[280][281]. - The company was awarded a jury trial verdict of $34 million, which includes $5.5 million in lost profits damages and $28.5 million in royalty damages for the commercial sales of the Hydrus Microstent[283]. - The patents involved in the lawsuit include U.S. Patent Nos. 8,287,482, 9,370,443, and 11,389,328, with ongoing reexamination proceedings that could adversely affect the company's ability to collect damages and ongoing royalties[283]. - The company is currently involved in trademark litigation in the UK and EU regarding the use of the OMNI trademark, which could impact its business operations in those markets[291]. Economic and Market Conditions - Uncertainty in global economic and political conditions may adversely affect product demand and financial results, potentially leading to material deviations from expectations[203]. - Healthcare costs have risen significantly, leading to cost reform initiatives and a consolidation trend in the healthcare industry, which may exert downward pressure on product prices[224]. - Recent changes in local coverage determinations (LCDs) have adversely impacted the company's OMNI sales results, contributing to ongoing uncertainty among investors[329]. - The market price of the company's common stock may fluctuate significantly due to various factors, including changes in reimbursement coverage and operating performance[327]. - The company has not yet faced securities litigation, but the risk is heightened during periods of stock price volatility, which could divert resources and harm its reputation[330].

Core Insights - Sight Sciences, Inc. reported a solid fourth quarter with a return to growth in Interventional Glaucoma and encouraging traction in Interventional Dry Eye, emphasizing the strength of its technologies and infrastructure in the eye care market [3][4]. Financial Highlights - Fourth quarter 2025 revenue was $20.4 million, a 7% increase year-over-year, with Interventional Glaucoma revenue at $19.7 million (up 5%) and Interventional Dry Eye revenue at $0.7 million (up from $0.3 million) [4][8]. - Gross profit for Q4 2025 was $17.8 million, with a gross margin of 87%, consistent with the prior year [5][10]. - Total operating expenses decreased by 25% to $21.5 million in Q4 2025, driven by lower personnel-related expenses and stock-based compensation [6][11]. - The net loss for Q4 2025 was $4.2 million, or $0.08 per share, compared to a net loss of $11.8 million, or $0.23 per share, in the same period the previous year [7][12]. Full Year 2025 Results - Total revenue for 2025 was $77.4 million, a 3% decrease from 2024, with Interventional Glaucoma revenue flat at $75.7 million and Interventional Dry Eye revenue dropping to $1.6 million from $4.0 million [8][9]. - Gross margin for the full year was 86%, up from 85% in 2024, with Interventional Dry Eye gross margin increasing to 59% from 46% [10][11]. - Total operating expenses for 2025 were $103.8 million, a 13% decrease from 2024, with significant reductions in research and development and selling, general, and administrative expenses [11][12]. - The net loss for 2025 was $38.4 million, or $0.74 per share, an improvement from a loss of $51.5 million, or $1.03 per share, in 2024 [12][13]. 2026 Financial Guidance - The company expects 2026 revenue to range from $82 million to $88 million, representing growth of 6% to 14% compared to 2025, with Interventional Glaucoma revenue projected at $77 million to $81 million and Interventional Dry Eye revenue at $5 million to $7 million [14][15]. - Adjusted operating expenses for 2026 are anticipated to be between $93 million and $96 million, reflecting an increase of 6% to 9% due to targeted investments in both business segments [15].